U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Safety
  3. Recalls, Market Withdrawals, & Safety Alerts
  4. Apotex Corp. Issues Voluntary Nationwide Recall of Ranitidine Tablets 75mg and 150mg (All pack sizes and Formats) due to the potential for Detection of an Amount of Unexpected Impurity,N-nitrosodimethylamine (NDMA) Impurity in the product
  1. Recalls, Market Withdrawals, & Safety Alerts

COMPANY ANNOUNCEMENT

Apotex Corp. Issues Voluntary Nationwide Recall of Ranitidine Tablets 75mg and 150mg (All pack sizes and Formats) due to the potential for Detection of an Amount of Unexpected Impurity,N-nitrosodimethylamine (NDMA) Impurity in the product

When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company's announcement as a public service. FDA does not endorse either the product or the company.

Read Announcement

Summary

Company Announcement Date:
FDA Publish Date:
Product Type:
Drugs
Reason for Announcement:
Recall Reason Description
Contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA)
Company Name:
Apotex Corp.
Brand Name:
Brand Name(s)
Apotex Corp.
Product Description:
Product Description
Ranitidine Tablets 75mg and 150mg

Company Announcement

Apotex Corp. is voluntarily, on a precautionary basis, recalling Ranitidine Tablets 75mg and 150mg (All pack sizes and Formats) to the Retail level. Apotex has learned from the U.S. Food and Drug Administration and other Global regulators that some ranitidine medicines including brand and generic formulations of ranitidine regardless of the manufacturer, contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. To date, Apotex has not received any reports of adverse events related to use of the product.

Risk Statement: NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.

Ranitidine Hydrochloride Tablet is an over the counter (OTC) oral product indicated for the relief of heartburn associated with acid indigestion and sour stomach and prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods and beverages. The affected Ranitidine Hydrochloride Tablets can be identified by NDC numbers stated on the product label.  

Product Strength Pack Size NDC Number
Ranitidine tablets, USP 150mg- acid reducer (Rite Aid) 150 mg 50's Bottle 11822-6052-1
Ranitidine tablets, USP 150mg- acid reducer (Rite Aid) 150 mg 65's Bottle 11822-6052-2
Ranitidine tablets, USP 150mg- acid reducer (Rite Aid) 150 mg 95's Bottle 11822-4727-3
Ranitidine tablets, USP 150mg- acid reducer (Walmart) 150 mg 65's Bottle 49035-117-06
Ranitidine tablets, USP 150mg- acid reducer (Walmart) 150 mg 24's Bottle 49035-100-00
Wal-Zan® 150 RANITIDINE TABLETS, USP 150 mg / ACID REDUCER (WALGREENS) 150 mg 200's Bottle 0363-1030-07
Product Strength Pack Size NDC Number
Ranitidine tablets, USP 150 mg - acid reducer (Rite Aid) 150 mg 24's Bottle 11822-6051-8
Ranitidine tablets, USP 150mg- acid reducer (Walmart) 150 mg 130's Bottle 49035-100-07
Wal-Zan® 150 RANITIDINE TABLETS, USP 150 mg / ACID REDUCER (WALGREENS) 150 mg 24's Bottle 0363-1013-02
Wal-Zan® 75 RANITIDINE TABLETS, USP 75 mg / ACID REDUCER (WALGREENS) 75 mg 30's Bottle 0363-1029-03
Cool mint Ranitidine tablets, USP 150 mg - acid reducer (Rite Aid) 150 mg 24's Bottle 11822-6107-4
Wal-Zan® 150 RANITIDINE TABLETS, USP 150 mg / ACID REDUCER (WALGREENS) 150 mg 65's Bottle 0363-1030-06
Wal-Zan® 150 RANITIDINE TABLETS, USP 150 mg / ACID REDUCER (WALGREENS) 150 mg 95's Bottle 0363-1030-09

The affected Ranitidine Hydrochloride Tablets were distributed Nationwide to Warehousing Chains. Apotex Corp.  has notified its affected direct account Warehousing Chains via mail (FedEx Standard Overnight) by mailing a recall notification letter and is arranging for return of all recalled product.

Wholesalers, Distributors and Retailers return the impacted product to place of purchase. Anyone with an existing inventory of the product should quarantine the recalled lots immediately.  Customers who purchased the impacted product directly from Apotex can call Inmar Rx Solutions at 800-967-5952 (option 1) (9:00am – 5:00-pm, EST Monday thru Friday), to arrange for their return.

Consumers with questions regarding this recall can contact Apotex corp.  by phone-number 1-800-706-5575 (8:30am – 5:00pm, EST Monday thru Friday) or email address UScustomerservice@Apotex.com. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online
  • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Company Contact Information

Consumers:
Apotex corp.
1-800-706-5575
UScustomerservice@Apotex.com
Media:
Jordan Berman
1 (416) 749-9026 Ext. 7487
jberman@apotex.com
Back to Top